Article Text

Download PDFPDF
Elevated Serum Uric Acid Predicts Angiographic Impaired Reperfusion and 1-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention
  1. Nurcan Basar, MD*,
  2. Nihat Sen, MD*,
  3. Firat Ozcan, MD*,
  4. Gonul Erden, MD,
  5. Selcuk Kanat, MD*,
  6. Erdogan Sokmen, MD*,
  7. Ahmet Isleyen, MD*,
  8. Huseyin Yuzgecer, MD*,
  9. Mehmet Fatih Ozlu, MD*,
  10. Metin Yildirimkaya, MD,
  11. Orhan Maden, MD*,
  12. Adrian Covic, MD,
  13. Richard J. Johnson, MD§,
  14. Mehmet Kanbay, MD
  1. From the *Department of Cardiology, Yuksek Ihtisas Education and Research Hospital; †Department of Clinical Biochemistry, Ankara Numune Research and Training Hospital, Ankara, Turkey; ‡Nephrology Clinic, Dialysis and Renal Transplant Center, 'C.I. PARHON' University Hospital, 'Gr. T. Popa' University of Medicine and Pharmacy, Iasi, Romania; §Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO; and ∥Department of Medicine, Division of Nephrology, Gulhane School of Medicine, Ankara, Turkey.
  1. Received November 25, 2010, and in revised form January 18, 2011.
  2. Accepted for publication January 18, 2011.
  3. Reprints: Mehmet Kanbay, MD, Gokkusagi Mahallesi, Umit sokak, No: 25/14, Melikgazi, Kayseri, Turkey. E-mail: drkanbay{at}
  4. Disclosure: Dr Richard Johnson has several patent applications related to the lowering of uric acid as a means to prevent or reverse hypertension and metabolic syndrome. The other authors disclose no conflict of interest.


Background Serum uric acid (SUA) is associated with microvascular disease that could alter coronary blood flow and prognosis. We evaluated the effects of admission SUA levels on coronary blood flow and prognosis in 185 consecutive patients with ST-segment elevation myocardial infarction (STEMI) who underwent acute primary percutaneous coronary intervention (PCI).

Methods Patients undergoing PCI for an acute STEMI were stratified into elevated SUA (>6.5 mg/dL) and normal SUA group (≤6.5 mg/dL). Primary end points were post-PCI myocardial blood flow and in-hospital and 1-year mortality.

Results Serum uric acid level was high in 45 patients (24%) on admission. Subjects with elevated SUA had a higher prevalence of hypertension, previous myocardial infarction, multivessel disease, and Killip functional class III or higher. Corrected thrombolysis in myocardial infarction (TIMI) frame count was longer, and mean TIMI myocardial perfusion grade was higher in patients with elevated uric acid compared with controls. Patients with elevated SUA levels had higher in-hospital (6.6% vs 2.8%, P < 0.01) and 1-year mortality (11.1% vs 5.7%, P < 0.01). Major adverse cardiac events were higher in patients with elevated SUA levels both in-hospital (11.1% vs 5.7%, P < 0.01) and at 1 year (17.7% vs 10%, P < 0.05). An elevated admission SUA level also independently predicted both 1-year mortality (odds ratio, 1.41; 95% confidence interval, 1.24-2.69) and abnormal myocardial perfusion detected by TIMI myocardial perfusion grade in STEMI patients undergoing primary PCI (odds ratio, 2.14; 95% confidence interval, 1.17-4.19, respectively).

Conclusions Elevated SUA level on admission independently predicts impaired myocardial flow and poor prognosis in STEMI patients undergoing primary PCI.

Key Words
  • uric acid
  • ST-segment elevation myocardial infarction
  • mortality
  • primary percutaneous coronary intervention

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.